28 nov.: Quam Announces 2012/13 Interim Results
28 nov.: UPDATE: South Korea October Current-Account Surplus Narrows; Beat..
28/11/2012 03:28:00

Korea Finance Corp: To Extend Due-Diligence Period for Korea Aerospace Sale to Dec 7

By Kanga Kong

SEOUL--Major shareholders of Korea Aerospace Industries Ltd. (0478410.SE) have extended by two weeks the due diligence process for the bidding of their combined 41.8% stake in the airplane components maker, worth an estimated $1 billion.

"We decided to extend the due-diligence period to Dec. 7 and take final bids by Dec. 17 due to the requests by preliminary bidders," Korea Finance Corp., KAI's largest shareholder, said Wednesday in a statement.

Two preliminary bidders, Korean Air Lines Co. (003490.SE) and Hyundai Heavy Industries, have asked the sellers for an extension, saying they couldn't complete due diligence by Nov. 23, as originally scheduled, as they faced strong resistance from KAI's labor union to complete the process.

Most analysts say the deal is unlikely to close by the year-end--as targeted by the key shareholders--or may fall through as some lawmakers are against the deal, particularly ahead of the presidential election on Dec. 19.

The deal is valued around 1.12 trillion won based on KAI's Tuesday closing price of KRW27,450.

The planned sale is the second after shareholders failed in August to attract sufficient bidding interest, with Korean Air being the sole bidder then. Under Korean law, any auction of state-owned company's assets must attract at least two bidders before it can proceed.

Korea Finance is selling 26.4% of KAI with the remaining 15.4%stake being sold by Hyundai Motor Co. (HYMLY), Doosan Group and Samsung Techwin Co. (012450.SE).

Korea Aerospace was formed in 1999 through the merger of the aerospace divisions of Samsung, Hyundai and the now-defunct Daewoo Group, during the 1997-98 Asian financial crisis.

Write to Kanga Kong at kanga.kong@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

November 27, 2012 21:28 ET (02:28 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

28 nov.: Quam Announces 2012/13 Interim Results
28 nov.: UPDATE: South Korea October Current-Account Surplus Narrows; Beat..

Envoyer un commentaire

Related debate

  • 1 semaine
  • 1 mois
  • 1 an
26 juil.
 
Pouli,   Forum er i den grad domineret af børn, studerende, ludomaner, buffet-wannabees and what hav..
24
28 juil.
GEN
Der er lidt nyt fra Morphosys angående deres CD38 antistof - det lader heldigvis til at gå lidt lang..
17
30 juil.
 
Jeg er helt vild med vendingen "og investere mine penge i aktier ud fra en strategi jeg mener vil sl..
13
29 juil.
FING-B
XO/Sologstrand, Mackeith, Vildum, Swiftnick og andre FING-skeptikere   1) Er vi enige i, at markedet..
12
28 juil.
 
Dejligt at der er nogen som kan svare "sobert" på et stillet spørgsmål.   Svaret kan indeholde ironi..
12
24 juil.
OMXN40
Det bliver/er hverdagskost i alle europæiske lande inden længe.. Men tankevækkende, at terrortruslen..
12
25 juil.
EXQ
Så lykkedes det at komme til Vedbæk for at besøge Exiqon. Damen, en kammerat og jeg selv blev taget ..
11
29 juil.
BIOPOR
I er tydeligvis enormt begavede og succesfulde alle tre. Men kunne det være muligt for jer at måle j..
10
27 juil.
 
Jeg har opdateret mine udbyttelister med tilbagekøb.   http://www.proinvestor.com/boards/69564/    
10
28 juil.
VELO
28/07/2014 08:30:00 - OMX Copenhagen, News     VELO: Veloxis Pharmaceuticals A/S - Envarsus ® får ..
9

Actualité la plus lue

  • 24 heures
  • 48 heures
  • 1 semaine
1
UNIBAIL-RODAMCO SE : accord avec Carmila pour céder un portefeuille de 931 M€ de six centres commerciaux en France
2
Sanofi et Regeneron rapportent les premiers résultats positifs de neuf études de Phase 3 consacrées à l'alirocumab dans le traitement de l'hypercholestérolémie
3
AB Science renouvelle sa ligne de financement en fonds propres (PACEO) avec Société Générale
4
CORRECTION:Gfi Informatique : Résultats semestriels 2014 : Annexes
5
Sanofi et Regeneron prévoient d'utiliser un droit d'accès à un examen prioritaire pour la demande d'approbation d'alirocumab auprès de la FDA des États-Unis
Euroinvestor dans le monde entier: Euroinvestor.dk | Euroinvestor.se | Euroinvestor.no | Euroinvestor.com | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Droit d'auteur Euroinvestor A/S 2014   Mentions légales et conditions d'utilisation
Information sur les cours fournies par Interactive Data.
Les données sont différées de 15 à 20 minutes selon les accords avec les différentes bourses internationales.
 
jeudi 31 juillet 2014 09:22:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB7 - 2014-07-31 09:22:09 - 2014-07-31 09:22:09 - 4 - Website: OKAY